Wycena firm — Medical Labs
Dla kogo jest ta wycena
Independent laboratory owners evaluating acquisition by national lab chains or hospital systems, PE investors building specialty diagnostics platforms, and health systems assessing captive lab value.
Co napędza wartość w branży Medical Labs
- Revenue per accession (test) and payer mix quality
- CLIA and CAP accreditation maintaining operational licenses
- Proprietary test menu and esoteric testing capabilities
- Client breadth (physician groups, hospitals, employers) and concentration
- Instrument utilization and throughput capacity for scaling
- Regulatory compliance record and proficiency testing history
Metody wycen, które stosujemy
Medical laboratories are valued at 8–14× EBITDA for specialty and esoteric labs, and 5–9× for general reference labs. Revenue multiples (1–2.5×) provide secondary benchmarks. This tool is informational only. Output is driven by your inputs and does not constitute a formal appraisal or certified valuation.
Typowe metryki i dane wejściowe
Revenue per accession
Average revenue per test or panel; higher for esoteric and specialty tests versus commodity chemistry.
Test volume growth
Year-over-year growth in accession count; indicates sales force and provider network effectiveness.
EBITDA margin
Typically 18–30% for specialty labs; 8–18% for general reference labs.
Commercial payer %
Revenue from commercial insurance; higher commercial mix improves reimbursement rates.
Client concentration
Revenue share from top 5 ordering physicians/groups; >25% creates concentration risk.
Przykładowe scenariusze
Specialty toxicology lab
A toxicology lab with $5 M revenue, 25% EBITDA margin, and strong pain management physician relationships might be valued at 9–12× EBITDA.
General reference lab
A general clinical lab processing routine chemistry and hematology with $8 M revenue and 15% EBITDA might trade at 6–8× EBITDA.
Często zadawane pytania
What multiple does a clinical lab sell for?
Specialty and esoteric labs: 8–14× EBITDA. General reference labs: 5–9× EBITDA. Unique proprietary tests or rare accreditations can drive premiums.
Why are CLIA and CAP accreditations important in lab valuation?
These accreditations are required for Medicare/Medicaid billing and commercial contracts. Losing them would eliminate most revenue - they're non-negotiable assets.
How does payer mix affect lab value?
Commercial insurance pays significantly more than Medicare clinical lab fee schedule. Labs with 40%+ commercial mix earn higher margins and command premium multiples.
What do national lab chains look for in acquisitions?
Geographic fill-in for existing client networks, specialty test capabilities they lack, and established physician relationships with low client concentration.
Is this a certified appraisal?
No. This tool provides informational estimates. For formal lab M&A, engage a healthcare industry advisor.
Uruchom swoją wycenę — Medical Labs
Otrzymaj profesjonalny raport wyceny oparty na DCF, spółkach porównywalnych, transakcjach precedensowych i analizie scenariuszy — za jedyne 199 USD.
Powiązane branże
Healthcare Services
Value a healthcare services company using EBITDA multiples, revenue per provider, and payer mix analysis. AI-powered reports for $199.
Clinic Rollup / DSO
Value a DSO, optometry rollup, or multi-specialty clinic platform using EBITDA multiples and site-level economics. Reports for $199.
Biotech & Pharma
Value a biotech or pharmaceutical company using rNPV, pipeline analysis, and pharma comparable transactions. AI-powered reports for $199.
Healthcare Devices
Value a medical device company using revenue multiples, regulatory clearance premium, and pipeline analysis. Reports for $199.